Table of Content

1. Overview
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitation
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Process
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews With Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Market Share Analysis
2.3.3. Growth Forecast Approach
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Rising Prevalence of Chronic Diseases Coupled With the Increasing Geriatric Population
4.2.2. Rising Prevalence of Infectious Diseases
4.2.3. Growing Demand for Point-of-Care (PoC) and Rapid Diagnostics
4.2.4. Rising Awareness Regarding Early Disease Diagnosis
4.2.5. Rising Healthcare Expenditures
4.2.6. Increasing Funding for Research Activities
4.3. Restraints
4.3.1. Stringent Technical Requirements and Regulatory Processes for High/Moderate-Complexity Tests
4.3.2. Variance in Test Results Observed in Rapid IVD Tests
4.4. Opportunities
4.4.1. Emerging Economies
4.4.2. Increasing Inclination Toward Personalized Medicine
4.4.3. Advancements in Genomics and Proteomics
4.5. Challenges
4.5.1. Evolving Regulatory Landscape
4.6. Technology Trends
4.6.1. Integration of Artificial Intelligence & Machine Learning in Molecular Diagnostics
4.6.2. Development of Smartphone-based Detection Platforms for Rapid Diagnostic Tests
4.6.3. Increasing Applications of Next-generation Sequencing Technology

5. In Vitro Diagnostics (IVD) Market: Regulatory Analysis
5.1. Overview
5.2. North America
5.2.1. U.S.
5.2.2. Canada
5.3. Europe
5.4. Asia-Pacific
5.4.1. China
5.4.2. Japan
5.4.3. India
5.5. Latin America
5.6. Middle East

6. In Vitro Diagnostics (IVD) Market Assessment?by Offering
6.1. Overview
6.2. Reagents & Kits
6.3. Systems
6.4. Software & Services

7. In Vitro Diagnostics (IVD) Market Assessment?by Technology
7.1. Overview
7.2. Molecular Diagnostics
7.2.1. Polymerase Chain Reaction (PCR)
7.2.2. Hybridization
7.2.3. Isothermal Nucleic Acid Amplification Technology
7.2.4. DNA Sequencing & Next-Generation Sequencing
7.2.5. Microarrays
7.2.6. Mass Spectrometry
7.2.7. Other Molecular Diagnostic Technologies
7.3. Point-of-Care (PoC) Diagnostics
7.3.1. Lateral Flow Assays/Rapid Tests
7.3.2. PoC Molecular Diagnostics
7.3.3. Other PoC Products
7.4. Immunoassay/Immunochemistry
7.4.1. Enzyme-linked Immunosorbent Assays (ELISA)
7.4.2. Enzyme-linked Immunospot Assays (ELISPOT)
7.4.3. Western Blotting
7.4.4. Radioimmunoassay
7.5. Biochemistry/Clinical Chemistry
7.5.1. Metabolic Panels
7.5.2. Electrolyte Panels
7.5.3. Liver Panels
7.5.4. Lipid Profiles
7.5.5. Renal Profiles
7.5.6. Thyroid Function Panels
7.6. Whole Blood Glucose Monitoring
7.7. Microbiology
7.8. Hematology
7.9. Coagulation/Hemostasis
7.10. Urinalysis
7.11. Other IVD Technologies

8. In Vitro Diagnostic (IVD) Market?by Application
8.1. Overview
8.2. Infectious Diseases
8.2.1. COVID-19 Testing
8.2.2. Sexually Transmitted Diseases (STD) Testing
8.2.3. Healthcare-associated Infections (HAIs)
8.2.4. Hepatitis
8.2.5. HIV
8.2.6. Tropical Diseases
8.2.7. Influenza
8.2.8. Respiratory Infections (Excluding Influenza)
8.2.9. Other Infectious Diseases
8.3. Oncology
8.4. Diabetes
8.5. Cardiology
8.6. Nephrology
8.7. Autoimmune Disorders
8.8. Other Applications

9. In Vitro Diagnostics (IVD) Market Assessment?by Diagnostic Approach
9.1. Overview
9.2. Laboratory Testing
9.3. OTC/Self Testing
9.4. Point-of-Care Testing

10. In Vitro Diagnostics (IVD) Market?by End User
10.1. Overview
10.2. Hospitals & Clinics
10.3. Diagnostic Laboratories
10.4. Home Healthcare
10.5. Other End Users

11. In Vitro Diagnostics (IVD) Market Assessment, by Geography
11.1. Overview
11.2. North America
11.2.1. U.S.
11.2.2. Canada
11.3. Europe
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Switzerland
11.3.7. Rest of Europe
11.4. Asia-Pacific
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. South Korea
11.4.5. Australia
11.4.6. Rest of Asia-Pacific
11.5. Latin America
11.5.1. Brazil
11.5.2. Mexico
11.5.3. Argentina
11.5.4. Rest of Latin America
11.6. Middle East
11.6.1. Saudi Arabia
11.6.2. Rest of Middle East
11.7. Africa
11.7.1. South Africa
11.7.2. Rest of Africa
12. Competitive Landscape
12.1. Overview
12.2. Key Growth Strategies
12.3. Competitive Dashboard
12.3.1. Industry Leaders
12.3.2. Market Differentiators
12.3.3. Vanguards
12.3.4. Emerging Companies
12.4. Vendor Market Positioning
12.5. Market Share Analysis (2022: Top 15 Players)
12.5.1. F. Hoffman-La Roche Ltd. (Switzerland)
12.5.2. Abbott Laboratories (U.S.)
12.5.3. Danaher Corporation (U.S)
12.5.4. Siemens Healthineers AG (Germany)
12.5.5. Thermo Fisher Scientific Inc. (U.S.)
13. Company Profiles
13.1. Abbott Laboratories
13.2. Becton, Dickinson and Company
13.3. biom?rieux S.A.
13.4. Danaher Corporation
13.5. F. Hoffman-La Roche Ltd
13.6. Qiagen N.V.
13.7. Siemens Healthineers AG (A Subsidiary of Siemens AG)
13.8. Thermo Fisher Scientific Inc.
13.9. Bio-Rad Laboratories, Inc.
13.10. Wama Diagnostica
13.11. lllumina, Inc.
13.12. Wiener Laboratories SAIC
13.13. Shenzhen Mindray Bio-Medical Electronics Co., Ltd
13.14. QuidelOrtho Corporation
13.15. Agilent Technologies, Inc.
13.16. DiaSorin S.p.A.

14. Appendix
14.1. Available Customization
14.2. Related Reports



List of Figures

List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Size Estimation
Figure 7 Global In Vitro Diagnostics (IVD) Market, by Offering, 2023 Vs. 2030 (USD Million)
Figure 8 Global in Vitro Diagnostic (IVD) Market, by Technology, 2023 Vs. 2030 (USD Million)
Figure 9 Global in Vitro Diagnostic Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 10 Global in Vitro Diagnostic Market, by Diagnostic Approach, 2023 Vs. 2030 (USD Million)
Figure 11 Global in Vitro Diagnostic Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 12 Global IVD Market, by Geography
Figure 13 Factors Affecting Market Growth
Figure 14 U.S.: Medical and Health R&D Expenditure, 2016–2020 (USD Billion)
Figure 15 Global Biopharmaceutical R&D Expenditure, 2016–2028 (USD Billion)
Figure 16 USFDA Regulatory Pathways for IVD Kits
Figure 17 EU Regulatory Pathway - IVDR 2017/746
Figure 18 China: Medical Device Classification and Pre-Market Requirements for IVD Devices
Figure 19 Global In Vitro Diagnostics (IVD) Market, by Offering, 2023 Vs. 2030 (USD Million)
Figure 20 Global in Vitro Diagnostic Market, by Technology, 2023 Vs. 2030 (USD Million)
Figure 21 Global In Vitro Diagnostics Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 22 U.S.: Estimated Acute Hepatitis C Cases, 2011–2020
Figure 23 Estimated Number of New Cancer Cases, by Region, 2020–2040 (Million)
Figure 24 Total Number of Accredited Testing Laboratories (ISO/IEC 17025), 2016–2020
Figure 25 Prevalence of Diabetes Across the World (In Million)
Figure 26 Global In Vitro Diagnostics Market, by Diagnostic Approach 2023 Vs. 2030 (USD Million)
Figure 27 Benefits of Laboratory Testing Approach
Figure 28 Benefits of the Point-of-Care Testing Approach
Figure 29 Global In Vitro Diagnostics Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 30 Global In Vitro Diagnostics Market, by Region, 2023 Vs. 2030 (USD Million)
Figure 31 North America: Number of People Aged 65 Years and Above, 2015–2021 (Million)
Figure 32 North America: Per Capita Health Expenditure (USD), 2017–2021
Figure 33 North America: In Vitro Diagnostics Market Snapshot
Figure 34 Canada: Number of People Aged 65 and Above, 2018–2022 (Million)
Figure 35 Europe: Number of People Aged 65 and Above (In Million) (2015–2021)
Figure 36 Europe: In Vitro Diagnostics Market Snapshot
Figure 37 France: Percentage of Population Aged 65 Years and Above (2016–2021)
Figure 38 France: Prevalence of Chronic Diseases in People Aged 65 and Above (2020)
Figure 39 U.K: Number of Cancer Cases, 2010–2030 (Million)
Figure 40 U.K.: Number of Diabetes and Urogenital, Blood, and Endocrine Disease Cases – DALYS (Disability-Adjusted Life Years), 2017–2020 (Thousand)
Figure 41 U.K.: Number of People Diagnosed With Sexually Transmitted Infections, 2018–2020 (Thousand)
Figure 42 Prevalence of HAI in Healthcare-Associated Infections in Acute-Care Wards (2016–2021)
Figure 43 Italy: Ovarian Cancer Cases Diagnosed (2018–2020)
Figure 44 Number of HIV Tests Performed in Catalonia (Spain) (2014–2021)
Figure 45 Switzerland: Number of New Cancer Cases (2020–2040)
Figure 46 Switzerland: Number of People Aged 65 Years and Above (2017–2021)
Figure 47 Asia-Pacific: In Vitro Diagnostics Market Snapshot
Figure 48 Japan: Percentage Share of the Geriatric Population (Aged 65 Years And Above) (2015–2022)
Figure 49 Japan: New Cancer Cases Reported (2020–2040)
Figure 50 China: Independent Medical Laboratories Market, 2015–2021 (USD Million)
Figure 51 India: Number of People Aged 65 Years and Above, 2017–2021 (Million)
Figure 52 Latin America: In Vitro Diagnostics Market Snapshot
Figure 53 Brazil: Challenges To the In Vitro Diagnostics Market
Figure 54 Middle East: In Vitro Diagnostics Market Snapshot
Figure 55 Saudi Arabia: Number of People Aged 65 Years and Above, 2017–2021 (Thousand)
Figure 56 Africa: In Vitro Diagnostics Market Snapshot
Figure 57 South Africa: Number of People (All Ages) Living With HIV, 2010–2020 (Million)
Figure 58 South Africa: Number of People With Diabetes, 2000–2045 (Thousand)
Figure 59 Key Growth Strategies Adopted by Leading Players (2019–2023)
Figure 60 Competitive Dashboard: Global In Vitro Diagnostics Market
Figure 61 Global In Vitro Diagnostics Market Competitive Benchmarking, by Offering
Figure 62 Market Share Analysis: Global In Vitro Diagnostics Market (2022)
Figure 63 Abbott Laboratories: Financial Overview (2021)
Figure 64 Becton, Dickinson and Company: Financial Overview (2022)
Figure 65 biom?rieux S.A.: Financial Overview (2021)
Figure 66 Danaher Corporation: Financial Overview (2021)
Figure 67 F. Hoffman-La Roche Ltd: Financial Overview (2021)
Figure 68 Qiagen N.V.: Financial Overview (2021)
Figure 69 Siemens Healthineers AG (A Subsidiary of Siemens AG): Financial Overview (2022)
Figure 70 Thermo Fisher Scientific Inc.: Financial Overview (2021)
Figure 71 Bio-Rad Laboratories: Financial Overview (2021)
Figure 72 Illumina, Inc.: Financial Overview (2021)
Figure 73 Shenzhen Mindray Bio-Medical Electronics Co., Ltd: Financial Overview (2021)
Figure 74 QuidelOrtho Corporation; Financial Overview (2021)
Figure 75 Agilent Technologies, Inc.: Financial Overview (2022)
Figure 76 DiaSorin S.p.A: Financial Overview (2021)